The neurobiological pathogenesis of poststroke depression

Chao Feng, Min Fang, Xue-Yuan Liu, Chao Feng, Min Fang, Xue-Yuan Liu

Abstract

Poststroke depression (PSD) is an important consequence after stroke, with negative impact on stroke outcome. The pathogenesis of PSD is complicated, with some special neurobiological mechanism, which mainly involves neuroanatomical, neuron, and biochemical factors and neurogenesis which interact in complex ways. Abundant studies suggested that large lesions in critical areas such as left frontal lobe and basal ganglia or accumulation of silent cerebral lesions might interrupt the pathways of monoamines or relevant pathways of mood control, thus leading to depression. Activation of immune system after stroke produces more cytokines which increase glutamate excitotoxicity, results in more cell deaths of critical areas and enlargement of infarctions, and, together with hypercortisolism induced by stress or inflammation after stroke which could decrease intracellular serotonin transporters, might be the key biochemical change of PSD. The interaction among cytokines, glucocorticoid, and neurotrophin results in the decrease of hippocampal neurogenesis which has been proved to be important for mood control and pharmaceutical effect of selective serotonin reuptake inhibitors and might be another promising pathway to understand the pathogenesis of PSD. In order to reduce the prevalence of PSD and improve the outcome of stroke, more relevant studies are still required to clarify the pathogenesis of PSD.

References

    1. Dafer RM, Rao M, Shareef A, Sharma A. Poststroke depression. Topics in Stroke Rehabilitation. 2008;15(1):13–21.
    1. Loubinoux I, Kronenberg G, Endres M, et al. Post-stroke depression: mechanisms, translation and therapy. Journal of Cellular and Molecular Medicine. 2012;16(9):1961–1969.
    1. Quaranta D, Marra C, Gainotti G. Post-stroke depression: main phenomenological clusters and their relationships with clinical measures. Behavioural Neurology. 2012;25(4):303–310.
    1. Robinson RG, Shoemaker WJ, Schlumpf M. Effect of experimental cerebral infarction in rat brain on catecholamines and behaviour. Nature. 1975;255(5506):332–334.
    1. Robinson RG, Kubos KL, Starr LB. Mood changes in stroke patients: relationship to lesion location. Comprehensive Psychiatry. 1983;24(6):555–566.
    1. Beblo T, Wallesch C, Herrmann M. The crucial role of frontostriatal circuits for depressive disorders in the postacute stage after stroke. Neuropsychiatry, Neuropsychology and Behavioral Neurology. 1999;12(4):236–246.
    1. Santos M, Kövari E, Gold G, et al. The neuroanatomical model of post-stroke depression: towards a change of focus? Journal of the Neurological Sciences. 2009;283(1-2):158–162.
    1. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Structure and Function. 2008;213(1-2):93–118.
    1. Tang WK, Lu JY, Chen YK, et al. Association of frontal subcortical circuits infarcts in poststroke depression: a magnetic resonance imaging study of 591 Chinese patients with ischemic stroke. Journal of Geriatric Psychiatry and Neurology. 2011;24(1):44–49.
    1. Vataja R, Pohjasvaara T, Leppavuori A, et al. Magnetic resonance imaging correlates of depression after ischemic stroke. Archives of General Psychiatry. 2001;58(10):925–931.
    1. Terroni L, Amaro E, Jr., Iosifescu DV, et al. Stroke lesion in cortical neural circuits and post-stroke incidence of major depressive episode: a 4-month prospective study. World Journal of Biological Psychiatry. 2011;12(7):539–548.
    1. Kronenberg G, Balkaya M, Prinz V, et al. Exofocal dopaminergic degeneration as antidepressant target in mouse model of poststroke depression. Biological Psychiatry. 2012;72(4):273–281.
    1. Dam H, Pedersen HE, Ahlgren P. Depression among patients with stroke. Acta Psychiatrica Scandinavica. 1989;80(2):118–124.
    1. MacHale SM, O’Rourke SJ, Wardlaw JM, Dennis MS. Depression and its relation to lesion location after stroke. Journal of Neurology Neurosurgery and Psychiatry. 1998;64(3):371–374.
    1. Wang Y, Zhang T, Jing X, et al. A prospective cohort study of lesion location and its relation to post-stroke depression among Chinese patients. Journal of Affective Disorders. 2012;136(1-2):e83–e87.
    1. Caeiro L, Ferro JM, Santos CO, Figueira ML. Depression in acute stroke. Journal of Psychiatry and Neuroscience. 2006;31(6):377–383.
    1. Aben I, Lodder J, Honig A, Lousberg R, Boreas A, Verhey F. Focal or generalized vascular brain damage and vulnerability to depression after stroke: a 1-year prospective follow-up study. International Psychogeriatrics. 2006;18(1):19–35.
    1. Snaphaan L, van der Werf S, Kanselaar K, de Leeuw F. Post-stroke depressive symptoms are associated with post-stroke characteristics. Cerebrovascular Diseases. 2009;28(6):551–557.
    1. Carson AJ, MacHale S, Allen K, et al. Depression after stroke and lesion location: a systematic review. The Lancet. 2000;356(9224):122–126.
    1. Yu L, Liu C, Chen J, Wang S, Wu Y, Yu S. Relationship between post-stroke depression and lesion location: a meta-analysis. Kaohsiung Journal of Medical Sciences. 2004;20(8):372–380.
    1. Bhogal SK, Teasell R, Foley N, Speechley M. Lesion location and poststroke depression: systematic review of the methodological limitations in the literature. Stroke. 2004;35(3):794–802.
    1. Vataja R, Leppävuori A, Pohjasvaara T, et al. Poststroke depression and lesion location revisited. Journal of Neuropsychiatry and Clinical Neurosciences. 2004;16(2):156–162.
    1. Nys GMS, van Zandvoort MJE, van der Worp HB, de Haan EHF, de Kort PLM, Kappelle LJ. Early depressive symptoms after stroke: neuropsychological correlates and lesion characteristics. Journal of the Neurological Sciences. 2005;228(1):27–33.
    1. Hickie I, Scott E, Mitchell P, Wilhelm K, Austin M, Bennett B. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biological Psychiatry. 1995;37(3):151–160.
    1. Salloway S, Malloy P, Kohn R, et al. MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology. 1996;46(6):1567–1574.
    1. Fujikawa T, Yamawaki S, Touhouda Y. Incidence of silent cerebral infarction in patients with major depression. Stroke. 1993;24(11):1631–1634.
    1. Krishnan KRR, Hays JC, Blazer DG. MRI-defined vascular depression. American Journal of Psychiatry. 1997;154(4):497–501.
    1. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. ‘Vascular depression” hypothesis. Archives of General Psychiatry. 1997;54(10):915–922.
    1. Alexopoulos GS. The vascular depression hypothesis: 10 years later. Biological Psychiatry. 2006;60(12):1304–1305.
    1. Sneed JR, Culang-Reinlieb ME. The vascular depression hypothesis: an update. American Journal of Geriatric Psychiatry. 2011;19(2):99–103.
    1. Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. Journal of Neurology, Neurosurgery and Psychiatry. 2008;79(6):619–624.
    1. Aizenstein HJ, Andreescu C, Edelman KL, et al. fMRI correlates of white matter hyperintensities in late-life depression. American Journal of Psychiatry. 2011;168(10):1075–1082.
    1. Vasudev A, Saxby BK, O'Brien JT, et al. Relationship between cognition, magnetic resonance white matter hyperintensities, and cardiovascular autonomic changes in late-life depression. American Journal of Geriatric Psychiatry. 2012;20(8):691–699.
    1. Grool AM, van der Graaf Y, Mali WPTM, WitkampTh.D. WD, Vincken KL, Geerlings MI. Location and progression of cerebral small-vessel disease and atrophy, and depressive symptom profiles: the Second Manifestations of ARTerial disease (SMART)-Medea study. Psychological Medicine. 2012;42(2):359–370.
    1. Sheline YI, Pieper CF, Barch DM, et al. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Archives of General Psychiatry. 2010;67(3):277–285.
    1. Alexopoulos GS, Bruce ML, Silbersweig D, Kalayam B, Stern E. Vascular depression: a new view of late-onset depression. Dialogues in Clinical Neuroscience. 1999;1(2):68–80.
    1. Brodaty H, Withall A, Altendorf A, Sachdev PS. Rates of depression at 3 and 15 months poststroke and their relationship with cognitive decline: the Sydney Stroke study. American Journal of Geriatric Psychiatry. 2007;15(6):477–486.
    1. Kim J, Park M, Yoon G, et al. White matter hyperintensity as a factor associated with delayed mood disorders in patients with acute ischemic stroke. European Neurology. 2011;66(6):343–349.
    1. Santos M, Gold G, Kövari E, et al. Differential impact of lacunes and microvascular lesions on poststroke depression. Stroke. 2009;40(11):3557–3562.
    1. Tennen G, Herrmann N, Black SE, et al. Are vascular risk factors associated with post-stroke depressive symptoms? Journal of Geriatric Psychiatry and Neurology. 2011;24(4):215–221.
    1. Pascoe MC, Crewther SG, Carey LM, Noonan K, Crewther DP, Linden T. Homocysteine as a potential biochemical marker for depression in elderly stroke survivors. Food & Nutrition Research. 2012;5614973
    1. Santos M, Kövari E, Hof PR, Gold G, Bouras C, Giannakopoulos P. The impact of vascular burden on late-life depression. Brain Research Reviews. 2009;62(1):19–32.
    1. Mast BT, MacNeill SE, Lichtenberg PA. Post-stroke and clinically-defined vascular depression in geriatric rehabilitation patients. American Journal of Geriatric Psychiatry. 2004;12(1):84–92.
    1. Parker G, Brotchie H. Mood effects of the amino acids tryptophan and tyrosine: “Food for Thought’. Acta Psychiatrica Scandinavica. 2011;124(6):417–426.
    1. Robinson RG, Bloom FE. Pharmacological treatment following experimental cerebral infarction: implications for understanding psychological symptoms of human stroke. Biological Psychiatry. 1977;12(5):669–680.
    1. Gao H, Zhu H, Zhang Y, Wang L. Reduction of cerebrospinal fluid and plasma serotonin in patients with post-stroke depression: a preliminary report. Clinical and Investigative Medicine. 2008;31(6):E351–E356.
    1. Winter C, von Rumohr A, Mundt A, et al. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behavioural Brain Research. 2007;184(2):133–141.
    1. Wang S, Zhang Z, Guo Y, Teng G, Chen B. Decreased expression of serotonin 1A receptor in the dentate gyrus in association with chronic mild stress: a rat model of post-stroke depression. Psychiatry Research. 2009;170(2-3):245–251.
    1. Cravello L, Caltagirone C, Spalletta G. The SNRI venlafaxine improves emotional unawareness in patients with post-stroke depression. Human Psychopharmacology. 2009;24(4):331–336.
    1. Kimura M, Kanetani K, Imai R, Suzuki H, Isayama K, Endo S. Therapeutic effects of milnacipran, a serotonin and noradrenaline reuptake inhibitor, on post-stroke depression. International Clinical Psychopharmacology. 2002;17(3):121–125.
    1. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews. 2009;61(2):105–123.
    1. Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacology Biochemistry and Behavior. 2012;100(4):656–664.
    1. McCarthy DJ, Alexander R, Smith MA, et al. Glutamate-based depression GBD. Medical Hypotheses. 2012;78(5):675–681.
    1. Musazzi L, Milanese M, Farisello P, et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS ONE. 2010;5(1)e8566
    1. Glodzik-Sobanska L, Slowik A, McHugh P, et al. Single voxel proton magnetic resonance spectroscopy in post-stroke depression. Psychiatry Research. 2006;148(2-3):111–120.
    1. Wang X, Li YH, Li MH, et al. Glutamate level detection by magnetic resonance spectroscopy in patients with post-stroke depression. European Archives of Psychiatry and Clinical Neuroscience. 2012;262(1):33–38.
    1. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nature Medicine. 2011;17(7):796–808.
    1. Müller N, Myint A, Schwarz MJ. Inflammatory biomarkers and depression. Neurotoxicity Research. 2011;19(2):308–318.
    1. Li M, Soczynska JK, Kennedy SH. Inflammatory biomarkers in depression: an opportunity for novel therapeutic interventions. Current Psychiatry Reports. 2011;13(5):316–320.
    1. Leonard BE. The concept of depression as a dysfunction of the immune system. Current Immunology Reviews. 2010;6(3):205–212.
    1. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuroendocrinology Letters. 2008;29(3):287–291.
    1. Pascoe MC, Crewther SG, Carey LM, Crewther DP. Inflammation and depression: why poststroke depression may be the norm and not the exception. International Journal of Stroke. 2011;6(2):128–135.
    1. Saito K, Suyama K, Nishida K, Sei Y, Basile AS. Early increases in TNF-α, IL-6 and IL-1β levels following transient cerebral ischemia in gerbil brain. Neuroscience Letters. 1996;206(2-3):149–152.
    1. Yamasaki Y, Matsuura N, Shozuhara H, et al. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke. 1995;26(4):676–681.
    1. Caso JR, Lizasoain I, Lorenzo P, Moro MA, Leza JC. The role of tumor necrosis factor-alpha in stress-induced worsening of cerebral ischemia in rats. Neuroscience. 2006;142(1):59–69.
    1. Fan T, Jiang WL, Zhu J, Zhang YF. Arctigenin protects focal cerebral ischemia-reperfusion rats through inhibiting neuroinflammation. Biological and Pharmaceutical Bulletin. 2012;35(11):2004–2009.
    1. Domaç FM, Somay G, Misirli H, Erenoglu NY. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke. Neurosciences. 2007;12(1):25–30.
    1. Wang S, Yuan Y, Xia W, et al. Neuronal apoptosis and synaptic density in the dentate gyrus of ischemic rats' response to chronic mild stress and the effects of notch signaling. PLoS ONE. 2012;7(8)e42828
    1. Semmler A, Okulla T, Sastre M, Dumitrescu-Ozimek L, Heneka MT. Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. Journal of Chemical Neuroanatomy. 2005;30(2-3):144–157.
    1. Kubera M, Obuchowicz E, Goehler L, Brzeszcz J, Maes M. In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(3):744–759.
    1. Kosten TA, Galloway MP, Duman RS, Russell DS, D’Sa C. Repeated unpredictable stress and antidepressants differentially regulate expression of the Bcl-2 family of apoptotic genes in rat cortical, hippocampal, and limbic brain structures. Neuropsychopharmacology. 2008;33(7):1545–1558.
    1. Tobe I, Ishida Y, Tanaka M, Endoh H, Fujioka T, Nakamura S. Effects of repeated maternal stress on Fos expression in the hypothalamic paraventricular nucleus of fetal rats. Neuroscience. 2005;134(2):387–395.
    1. Anderson CM, Swanson RA. Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia. 2000;32(1):1–14.
    1. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biological Psychiatry. 2009;65(9):732–741.
    1. Miller AH. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain, Behavior, and Immunity. 2009;23(2):149–158.
    1. Felger JC, Alagbe O, Hu F, et al. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biological Psychiatry. 2007;62(11):1324–1333.
    1. Zhu C, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology. 2006;31(10):2121–2131.
    1. Dantzer R, O’Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36(3):426–436.
    1. Mitchell AJ. Clinical implications of poststroke hypothalamo-pituitary adrenal axis dysfunction: a critical literature review. Journal of Stroke and Cerebrovascular Diseases. 1997;6(6):377–388.
    1. Johansson Å, Olsson T, Carlberg B, Karlsson K, Fagerlund M. Hypercortisolism after stroke—partly cytokine-mediated? Journal of the Neurological Sciences. 1997;147(1):43–47.
    1. Weidenfeld J, Leker RR, Gai N, Teichner A, Bener D, Ovadia H. The function of the adrenocortical axis in permanent middle cerebral artery occlusion: effect of glucocorticoids on the neurological outcome. Brain Research. 2011;1407:90–96.
    1. Astrom M, Olsson T, Asplund K. Different linkage of depression to hypercortisolism early versus late after stroke: a 3-year longitudinal study. Stroke. 1993;24(1):52–57.
    1. Herbert J, Goodyer IM, Grossman AB, et al. Do corticosteroids damage the brain? Journal of Neuroendocrinology. 2006;18(6):393–411.
    1. Holsboer-Trachsler E, Stohler R, Hatzinger M. Repeated administration of the combined dexamethasone-human corticotropin releasing hormone stimulation test during treatment of depression. Psychiatry Research. 1991;38(2):163–171.
    1. Carvalho LA, Pariante CM. In vitro modulation of the glucocorticoid receptor by antidepressants. Stress. 2008;11(6):411–424.
    1. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011;35(3):722–729.
    1. Pace TWW, Hu F, Miller AH. Activation of cAMP-protein kinase A abrogates STAT5-mediated inhibition of glucocorticoid receptor signaling by interferon-alpha. Brain, Behavior, and Immunity. 2011;25(8):1716–1724.
    1. Anisman H, Gibb J, Hayley S. Influence of continuous infusion of interleukin-1β on depression-related processes in mice: corticosterone, circulating cytokines, brain monoamines, and cytokine mRNA expression. Psychopharmacology. 2008;199(2):231–244.
    1. Reimold M, Knobel A, Rapp MA, et al. Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology. 2011;213(2-3):563–572.
    1. McEwen BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism. 2005;54(5):20–23.
    1. Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science. 2012;338(6103):72–75.
    1. Wang S, Zhang Z, Guo Y, Teng G, Chen B. Hippocampal neurogenesis and behavioural studies on adult ischemic rat response to chronic mild stress. Behavioural Brain Research. 2008;189(1):9–16.
    1. Schoenfeld TJ, Gould E. Stress, stress hormones, and adult neurogenesis. Experimental Neurology. 2012;233(1):12–21.
    1. Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology. 2012;37(9):1397–1416.
    1. Seguin JA, Brennan J, Mangano E, Hayley S. Proinflammatory cytokines differentially influence adult hippocampal cell proliferation depending upon the route and chronicity of administration. Neuropsychiatric Disease and Treatment. 2009;5(1):5–14.
    1. Masi G, Brovedani P. The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression. CNS Drugs. 2011;25(11):913–931.
    1. Yang L, Zhang Z, Sun D, et al. Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke. International Journal of Geriatric Psychiatry. 2011;26(5):495–502.
    1. Zhou Z, Lu T, Xu G, et al. Decreased serum Brain-Derived Neurotrophic Factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism. Clinical Chemistry and Laboratory Medicine. 2011;49(2):185–189.
    1. You Z, Luo C, Zhang W, et al. Pro- and anti-inflammatory cytokines expression in rat’s brain and spleen exposed to chronic mild stress: involvement in depression. Behavioural Brain Research. 2011;225(1):135–141.
    1. Numakawa T, Yokomaku D, Richards M, Hori H, Adachi N, Kunugi H. Functional interactions between steroid hormones and neurotrophin BDNF. World Journal of Biological Chemistry. 2010;1(5):133–143.
    1. Hama S, Yamashita H, Yamawaki S, Kurisu K. Post-stroke depression and apathy: interactions between functional recovery, lesion location, and emotional response. Psychogeriatrics. 2011;11(1):68–76.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner